This content is funded by Boehringer Ingelheim International GmbH.
Access the exclusive video of Boehringer Ingelheim’s Industry Sponsored Symposium at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer Symposium, which took place on September 9th, 2023 at the Suntec Singapore Convention and Exhibition Center.
Chair:
Byoung Chul Cho
Yonsei Cancer Center
Seoul, Korea
Herbert Loong
The Chinese University of Hong Kong,
Hong Kong
Yasushi Goto
National Cancer Center
Tokyo, Japan
The symposium titled “Past, Present, and Future of Personalized Care in Lung Cancer: HER2-Targeted and DLL3-Targeted Therapies in Focus” featured leading experts in the field of personalised therapy in lung cancer.
- Loong highlighted the close connection between the development of targeted therapies and the discovery of driver mutations. His presentation also delved into practical considerations in biomarker testing.
- Cho discussed a familiar biomarker, HER2, which has received renewed interest as a targetable alteration in non-small cell lung carcinoma. He presented the different HER2-targeting strategies and recent advancements in HER2-selective TKIs.
- Goto presented the challenges in treating small cell lung cancer and large cell neuroendocrine carcinomas of the lung. He then focused on the potential of DLL3 to be a biomarker in these diseases and possibly a target for T-cell engaging therapies.
